Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Li, JX; Wu, SP; Guo, XL; Tang, R; Huang, BY; Chen, XQ; Chen, Y; Hou, LH; Liu, JX; Zhong, J; Pan, HX; Shi, FJ; Xu, XY; Li, ZP; Zhang, XY; Cui, LB; Tan, WJ; Chen, W; Zhu, FC

Chen, W (通讯作者)，Acad Mil Med Sci, Beijing Inst Biotechnol, Beijing 100071, Peoples R China.;Zhu, FC (通讯作者)，Jiangsu Prov Ctr Dis Control & Prevent, NHC Key Lab Enter Pathogen Microbiol, Nanjing 210009, Peoples R China.

LANCET RESPIRATORY MEDICINE, 2022; 10 (8): 739

Abstract

Background Due to waning immunity and protection against infection with SARS-CoV-2, a third dose of a homologous or heterologous COVID-19 vaccine has ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索